tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Chris Shibutani, 70 are a BUY (54.69%), 54 are a HOLD (42.19%), 4 are a SELL (3.13%).
Analyst Chris Shibutani, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 55.37% that have a potential upside of 18.19% achieved within 113 days.
Chris Shibutani’s has documented 256 price targets and ratings displayed on 30 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on UTHR, United Therapeutics at 01-Nov-2024.
Analyst best performing recommendations are on RXDX (PROMETHEUS BIOSCIENCES).
The best stock recommendation documented was for RXDX (PROMETHEUS BIOSCIENCES) at 12/7/2022. The price target of $117 was fulfilled within 1 day with a profit of $21.2 (22.13%) receiving and performance score of 221.29.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$26
$-0.47 (-1.78%)
$32
14 days ago
(25-Oct-2024)
4/7 (57.14%)
$-0.09 (-0.34%)
26
Buy
$37
$10.53 (39.78%)
$39
14 days ago
(25-Oct-2024)
3/8 (37.5%)
$10.91 (41.82%)
101
Buy
$30
$3.53 (13.34%)
$37
14 days ago
(25-Oct-2024)
7/16 (43.75%)
$3.91 (14.99%)
389
Hold
$37
$10.53 (39.78%)
$37
14 days ago
(25-Oct-2024)
13/21 (61.9%)
$10.91 (41.82%)
244
Sell
$25
$-1.47 (-5.55%)
$31
8 months 19 days ago
(20-Feb-2024)
2/2 (100%)
$-5.39 (-17.74%)
86
Which stock is Chris Shibutani is most bullish on?
Which stock is Chris Shibutani is most reserved on?
What Year was the first public recommendation made by Chris Shibutani?
